EY
EyePoint Pharmaceuticals, Inc.
EYPT · NASDAQ
$4.07 +0.37% (+$0.02)
1M -17.45%
Market Cap $337.0M
P/E Ratio -
Div. Yield -
ROE 135.81%
Piotroski F-Score Weak
2/9Valuation
44 /100
Fair P/B 2.03x
P/S 120.85x
PEG N/A
Growth
22 /100
Declining Book val. growth 47.00%
Rev. growth 8.83%
FCF growth N/A
Profitability
17 /100
Weak FCF margin 9,726.75%
Op. margin 11,365.20%
Gross margin 41.77%
Quality
0 /100
Poor Asset turnover 0.01x
ROA 134.38%
ROIC 167.81%
Debt
100 /100
Low Current ratio 4.50x
Debt/Equity 0.13x
Net debt/EBITDA N/A
Stability
39 /100
Moderate Profitable years 0
EPS volatility 38.17%
Beta 1.64x
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na EYPT
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jay S. Duker
Employees
214
Headquarters
Watertown
Nadcházející události
04 LIS
Earnings
Upcoming earnings report